Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...
Sterling Investment Advisors Ltd. increased its holdings in Regeneron Pharmaceuticals by 23.5% during Q4. The firm now owns 3 ...
In a much-anticipated decision, the First Circuit unanimously ruled the government and relators must prove that a violation ...
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Intellia expects to present longer-term data from the ongoing Phase 1/2 study in 2025. The data will include patients in the ...
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results